Coping strategies and interventions for cognitive changes in patients with cancer

Seminars in Oncology Nursing

Volumn 29, Issue 4, 2013, Pages 288-299

  Von Ah, Diane ^a   Storey, Susan ^a   Jansen, Catherine E ^b   Allen, Deborah H ^c  

^a INDIANA UNIVERSITY SCHOOL OF NURSING   (United States)

^b KAISER PERMANENTE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Cognition; Coping; Evidence based practice; Intervention

Indexed keywords

ADAPTIVE BEHAVIOR; ARTICLE; COGNITION; COPING BEHAVIOR; EVIDENCE BASED PRACTICE; HUMAN; INTERVENTION; NEOPLASM; PSYCHOLOGICAL ASPECT; SURVIVOR;

COGNITION; COPING; EVIDENCE-BASED PRACTICE; INTERVENTION;

ADAPTATION, PSYCHOLOGICAL; COGNITION; HUMANS; NEOPLASMS; SURVIVORS;

EID: 84887201288     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soncn.2013.08.009     Document Type: Article

References (71)

1. Anderson-Hanley C., Sherman M., Riggs R., et al. Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc 2003, 9:967-982.
2. Munir F., Burrows J., Yarker J., et al. Women's perceptions of chemotherapy-induced cognitive side affects on work ability: a focus group. J Clin Nurs 2010, 19:1362-1370.
3. Myers J.S. Chemotherapy-related cognitive impairment: the breast cancer experience. Oncol Nurs Forum 2012, 39:E31-E40.
4. Von Ah D., Habermann B., Carpenter J., et al. Impact of perceived cognitive impairment in breast cancer survivors. Eur J Oncol Nurs 2013, 17:236-241.
5. Thielen J.Z. The experience of neurocognitive changes in women undergoing chemotherapy for breast cancer 2008, University of Connecticut, Storrs, CT, Doctoral Dissertations. Paper AAI3308251. http://digitalcommons.uconn.edu/dissertations/AAI3308251.
6. Jansen C. Cognitive changes. Cancer basics 2010, 331-369. Oncology Nursing Society, Pittsburgh, PA. J. Eggert (Ed.).
7. Von Ah D., Russell K.M., Storniolo A.M., et al. Cognitive dysfunction and its relationship to quality of life in breast cancer survivors. Oncol Nurs Forum 2009, 36:326-336.
8. Reid-Arndt S.A., Hsieh C., Perry M.C. Neuropsychological functioning and quality of life during the first year after completing chemotherapy for breast cancer. Psychooncology 2010, 19:535-544.
9. Fitch M.I., Armstrong J., Tsang S. Patients' experiences with cognitive changes after chemotherapy. Can Oncol Nurs J 2008, 18:180-192.
10. Munir F. Cognitive intervention for breast cancer patients undergoing adjuvant chemotherapy: a needs analysis. Cancer Nurs 2011, 34:385-392.
11. Downie F.P., Mar Fan H.G., Houede-Tchen N., et al. Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment. Psychooncology 2006, 15:921-930.
12. Boykoff N., Moieni M., Subramanian S.K. Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response. J Cancer Surviv 2009, 3:223-232.
13. Sheridan M.A., Sherman M.L., Pierce T., et al. Social support, social constraint, and affect in spouses of women with breast cancert The role of cognitive processing. J Soc Pers Relat 2010, 27:5-22.
14. Lepore S.J., Silver R.C., Wortman C.B., et al. Social constraints, intrusive thoughts, and depressive symptoms among bereaved mothers. J Pers Soc Psychol 1996, 70:271-282.
15. Cancer.net. Attention, thinking or memory problems. Available at: (accessed February 10, 2013). http://www.cancer.net/all-about-cancer/treating-cancer/managing-side-effects/cognitive-problems.
16. Von Ah D., Jansen C., Allen D.H., et al. Putting evidence into practice: evidence-based interventions for cancer and cancer treatment-related cognitive impairment. Clin J Oncol Nurs 2011, 15:607-615.
17. Allen D., Von Ah D., Jansen C., et al. Cognitive impairment. Putting evidence into practice: improving patient outcomes 2011, Vol 2:607-615. Oncology Nursing Society, Pittsburgh, PA.
18. Fardell J.E., Vardy J., Johnston I.N., et al. Chemotherapy and cognitive impairment: treatment options. Clin Pharmacol Ther 2011, 90:366-376.
19. Vearncombe K.J., Rolfe M., Wright M., et al. Predictors of cognitive decline after chemotherapy in breast cancer patients. J Int Neuropsychol Soc 2009, 15:951-962.
20. O'Shaughnessy J.A. Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy. Clin Breast Cancer 2002, 3(suppl):S116-S120.
21. O'Shaughnessy J.A., Vukelja S.J., Holmes F.A., et al. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer 2005, 5:439-446.
22. Iconomou G., Koutras A., Karaivazoglou K., et al. Effect of epoetin alpha therapy on cognitive function in anaemic patients with solid tumours undergoing chemotherapy. Eur J Cancer Care (Engl) 2008, 17:535-541.
23. Mar Fan H.G., Park A., Xu W., et al. The influence of erythropoietin on cognitive function in women following chemotherapy for breast cancer. Psychooncology 2009, 18:156-161.
24. Massa E., Madeddu C., Lusso M.R., et al. Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy. Crit Rev Oncol Hematol 2006, 57:175-182.
25. Mancuso A., Migliorino M., De Santis S., et al. Correlation between anemia and functional/cognitive capacity in elderly lung cancer patients treated with chemotherapy. Ann Oncol 2006, 17:146-150.
26. Chang J., Couture F.A., Young S.D., et al. Weekly administration of epoetin alfa improves cognition and quality of life in patients with breast cancer receiving chemotherapy. Support Cancer Ther 2004, 2:52-58.
27. Meyers C.A., Wefel J.S. The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol 2003, 21:3557-3558.
28. US Food and Drug Administration. FDA drug safety communication: Erythropoiesis-stimulating agents (ESAs): procrit, epogen and aranesp. 2010. Available at: (accessed June 1, 2011). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm200297.htm.
29. Volz T.J. Neuropharmacological mechanisms underlying the neuroprotective effects of methylphenidate. Curr Neuropharmacol 2008, 6:379-385.
30. Bruera E., Miller M.J., Macmillan K., et al. Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain 1992, 48:163-166.
31. Butler J.M., Case L.D., Atkins J., et al. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys 2007, 69:1496-1501.
32. Gagnon B., Low G., Schreier G. Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study. J Psychiatry Neurosci 2005, 30:100-107.
33. Gehring K., Patwardhan S.Y., Collins R., et al. A randomized trial of efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with primary brain tumor. J Neurooncol 2012, 107:165-174.
34. Mar Fan H., Clemons M., Xu W., et al. A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer 2008, 16:577-583.
35. Lower E.E., Fleishman S., Cooper A., et al. Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage 2009, 38:650-662.
36. Schwartz A.L., Thompson J.A., Masood N. Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. Oncol Nurs Forum 2002, 29:E85-E90.
37. Meyers C.A., Weitzner M.A., Valentine A.D., et al. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 1998, 16:2522-2527.
38. Blackhall L., Petroni G., Shu J., et al. A pilot study evaluating the safety and efficacy of modafinal for cancer-related fatigue. J Palliat Med 2009, 12:433-439.
39. Kohli S., Fisher S.G., Tra Y., et al. The effect of modafinil on cognitive function in breast cancer survivors. Cancer 2009, 115:2605-2616.
40. Lundorff L.E., Jonsson B.H., Sjogren P. Modafinil for attentional and psychomotor dysfunction in advanced cancer: a double-blind, randomised, cross-over trial. Palliat Med 2009, 23:731-738.
41. Winocur G., Vardy J., Binns M.A., et al. The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice. Pharmacol Biochem Behav 2006, 85:66-75.
42. Jatoi A., Kahanic S.P., Frytak S., et al. Donepezil and vitamin E for preventing cognitive dysfunction in small cell lung cancer patients: preliminary results and suggestions for future study designs. Support Care Cancer 2005, 13:66-69.
43. Shaw E.G., Rosdhal R., D'Agostino R.B., et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol 2006, 24:1415-1420.
44. Ahles T.A., Saykin A.J. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 2007, 7:192-201.
45. Chan A.S., Cheung M.C., Law S.C., et al. Phase II study of alpha-tocopherol in improving the cognitive function of patients with temporal lobe radionecrosis. Cancer 2004, 100:398-401.
46. Bjelakovic G., Nikolova D., Gluud L.L., et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007, 297:842-857.
47. Miller E.R., Pastor-Barriuso R., Dalal D., et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005, 142:37-46.
48. Nada S.E., Shah Z.A. Preconditioning with Ginko biloba (EGb 761(R)) provides neuroptrotection through H01 and CRMP2. Neurobiol Dis 2012, 46:180-189.
49. Smith J.V., Luo Y. Studies on molecular mechanisms of Ginkgo biloba extract. Appl Microbiol Biotechnol 2004, 64:465-472.
50. Barton D.L., Burger K., Novonty P.J., et al. The use of Ginkgo Biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for cancer. Support Care Cancer 2012, 21:1185-1192.
51. Snitz B.E., O'Meara E.S., Carlson M.C., et al. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA 2009, 302:2663-2670.
52. Kaplan S. The restorative benefits of nature: toward an integrative framework. J Env Psychol 1995, 15:169-182.
53. Cimprich B. Development of an intervention to restore attention in cancer patients. Cancer Nurs 1993, 16:83-92.
54. Cimprich B., Ronis D.L. An environmental intervention to restore attention in women with newly diagnosed breast cancer. Cancer Nurs 2003, 26:284-292.
55. Hoffman C.J., Ersser S.J., Hopkinson J.B., et al. Effectiveness of mindfulness-based stress reduction in mood, breast- and endocrine-related quality of life, and well-being in stage 0-III breast cancer: A randomized, controlled trial. J Clin Oncol 2012, 30:1335-1342.
56. Speca M., Carlson L.E., Goodey E., et al. A randomized, wait-list controlled trial: The effect of mindfulness meditation-based stress reduction program on mood and symptoms of stress in cancer outpatients. Psychosom Med 2000, 62:613-622.
57. Kramer A.F., Erickson K.I., Colcombe S.J. Exercise, cognition and the aging brain. J App Physiol 2006, 101:1237-1242.
58. Korstjens I., Mesters I., van der Peet E., et al. Quality of life of cancer survivors after physical and psychosocial rehabilitation. Eur J Cancer Prev 2006, 15:541-547.
59. Baumann F.T., Drosselmeyer N., Leskaroski A., et al. 12-Week resistance training with breast cancer patients during chemotherapy: effects on cognitive abilities. Breast Care 2011, 6:142-143.
60. Reid-Arndt S.A., Matsuda S., Cox C.R. Tai chi effects on neuropsychological, emotional, and physical functioning: a pilot study. Cont Ther Clin Pract 2011, 18:26-30.
61. Oh B., Butow P.N., Mullan B.A., et al. Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trial. Support Care Cancer 2011, 20:1235-1242.
62. Ferguson R.J., Ahles T.A., Saykin A.J., et al. Cognitve-behavioral management of chemotherapy-related cognitive change. Psychooncology 2007, 16:772-777.
63. Ferguson R.J., McDonald B.C., Rocque M.A., et al. Development of CBT for chemotherapy-related cognitive change: results of a waitlist control trial. Psychooncology 2012, 21:176-186.
64. McDougall G.J. Memory improvement program for elderly cancer survivors. Geriatr Nurs 2001, 22:185-190.
65. Schuurs A., Green H.J. A feasibility study of group cognitive rehabilitation for cancer survivors: enhancing cognitive function and quality of life. Psychooncology 2012, 22:1043-1049.
66. McDougall G.J., Becker H., Acee T.W., et al. Symptom management of affective and cognitive disturbance with a group of cancer survivors. Arch Psychiatr Nurs 2011, 25:24-35.
67. Gehring K., Sitskoorn M.M., Gundy C.M., et al. Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial. J Clin Oncol 2009, 27:3712-3722.
68. Von Ah D., Carpenter J.S., Saykin A., et al. Advanced cognitive training for breast cancer survivors: a randomized controlled trial. Breast Cancer Res Treat 2012, 135:799-809.
69. Poppelreuter M., Weis J., Bartsch H.H. Effects of specific neuropsychological training programs for breast cancer patients after adjuvant chemotherapy. J Psychosoc Oncol 2009, 27:274-296.
70. Hassler M.R., Elandt K., Preusser M., et al. Neurocognitive training in patients with high-grade glioma: a pilot study. J Neurooncol 2010, 97:109-115.
71. Ball K., Berch D.B., Helmers K.F., et al. Effects of cognitive training interventions with older adults: a randomized controlled trial. JAMA 2002, 288:2271-2281.